ࡱ> {}xyz%` Ubjbj"x"x 4F@@M@@@@@@@B&8*Dn|h>(  :    0N d 4'''''''$*hh,0'@     '@@  ' @ @ ' '6@@   0~xxE 4(0>(, ^,8,@       ''x f   >(    hhhONMhhhN@A|B@@@@@@  SYNCHRON System(s) Chemistry Information Sheet NA Sodium REF 467935 REF 467915 REF A28937 REF A28945For In Vitro Diagnostic Use ANNUAL REVIEW Reviewed by:DateReviewed by:DatePRINCIPLE INTENDED USE ISE Electrolyte Buffer reagent and ISE Electrolyte Reference reagent, when used in conjunction with SYNCHRON LX System(s), UniCel DxC 600/800 System(s) and SYNCHRON Systems AQUA CAL 1, 2 and 3, are intended for the quantitative determination of sodium concentration in human serum, plasma or urine. CLINICAL SIGNIFICANCE Sodium measurements are used in the diagnosis and treatment of aldosteronism (excessive secretion of hormone aldosterone), diabetes insipidus, adrenal hypertension, Addison's disease, dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance. METHODOLOGY The SYNCHRON System(s) determines sodium ion concentration by indirect potentiometry utilizing two glass sodium electrodes (one acts as the reference electrode). To measure sodium concentrations, a precise volume of sample (40 microliters) is mixed with a buffered solution. The ratio used is one part sample to 33 parts buffer. The high molar strength buffer is used to establish a constant activity coefficient for sodium ions, calibrating the electrode to concentration values. CHEMICAL REACTION SCHEME The sodium electrode is made of lithium-sodium-aluminum-silicate glass. It is essential that the outer layer of the glass electrode is adequately hydrated. When the sample buffer mixture contacts the electrode, sodium ions in the sample undergo an ion exchange process with the sodium ions in the hydrated layer of the electrode. Changes in electrode potential occur as the ion exchange process takes place. These changes in electrode potential are referenced to the reference electrode. The "referenced potential" follows the Nernst equation and allows the calculation of sodium concentration in the sample:  For more accurate measurement, the reference reagent containing sodium ions is introduced into the flow cell after the sample cycle, and the same ion exchange process takes place. The differential potential (voltage) between sample and reference reagent cycles is used for the calculation. Under ideal conditions, the electrode imparts a selectivity of 300:1 over potassium and is insensitive to hydrogen ions in solutions buffered from pH 6 to 10. SPECIMEN TYPE OF SPECIMEN Biological fluid samples should be collected in the same manner routinely used for any laboratory test.REF "bibA1852928" \f \h \n 1 Freshly drawn serum, plasma or properly collected urine (random/timed) are the preferred specimens. Acceptable anticoagulants are listed in the PROCEDURAL NOTES section of this chemistry information sheet. Whole blood is not recommended for use as a sample. SPECIMEN STORAGE AND STABILITY 1.Tubes of blood are to be kept closed at all times and in a vertical position. It is recommended that the serum or plasma be physically separated from contact with cells within two hours from the time of collection.REF "bibA1852914" \f \h \n 2 2.Separated serum or plasma should not remain at room temperature longer than 8 hours. If assays are not completed within 8 hours, serum or plasma should be stored at +2C to +8C. If assays are not completed within 48 hours, or the separated sample is to be stored beyond 48 hours, samples should be frozen at -15C to -20C. Frozen samples should be thawed only once. Analyte deterioration may occur in samples that are repeatedly frozen and thawed.REF "bibA1852914" \f \h \n 2 3.It is recommended that urine assays be performed within 2 hours of collection. For timed specimens, the collection container should be kept in the refrigerator or on ice during the timed period. No preservative is required.REF "bibA18529278" \f \h \n 3 Additional specimen storage and stability conditions as designated by this laboratory: SAMPLE VOLUME A filled 0.5 mL sample cup is the optimum volume. For optimum primary sample tube volumes in primary tube samples and minimum volumes, refer to the Primary Tube Sample Template for your system. CRITERIA FOR UNACCEPTABLE SPECIMENS Refer to the PROCEDURAL NOTES section of this chemistry information sheet for information on unacceptable specimens. Criteria for sample rejection as designated by this laboratory: PATIENT PREPARATION Special instructions for patient preparation as designated by this laboratory: SPECIMEN HANDLING Special instructions for specimen handling as designated by this laboratory: REAGENTS CONTENTS Each kit contains the following items: ISE ELECTROLYTE BUFFER REAGENT: Two Electrolyte Buffer Reagent Bottles (2 x 2 L) ISE ELECTROLYTE REFERENCE REAGENT: Two Electrolyte Reference Reagent Bottles (2 x 2 L) VOLUMES PER TEST Sample Volume40 LReagent VolumeISE Electrolyte Buffer1.27 mLISE Electrolyte Reference3.23 mL(not part of sample dilution) REACTIVE INGREDIENTS REAGENT CONSTITUENTSISE ELECTROLYTE BUFFER REAGENT:Tris230 mmol/LISE ELECTROLYTE REFERENCE REAGENT:Sodium7 mmol/LPotassium0.2 mmol/LChloride5 mmol/LCarbon Dioxide1.5 mmol/LCalcium0.1 mmol/LAlso non-reactive chemicals necessary for optimal system performance.Avoid skin contact with reagent. Use water to wash reagent from skin. MATERIALS NEEDED BUT NOT SUPPLIED WITH REAGENT KIT SYNCHRON Systems AQUA CAL 1, 2 and 3 At least two levels of control material REAGENT PREPARATION No preparation is required. ACCEPTABLE REAGENT PERFORMANCE The acceptability of a reagent is determined by successful calibration and by ensuring that quality control results are within your facility's acceptance criteria. REAGENT STORAGE AND STABILITY 1.ISE Electrolyte Reference reagent stored unopened at room temperature is stable until the expiration date printed on the bottle label. Once opened, the reagent is stable at room temperature for 30 days, unless the expiration date is exceeded. 2.ISE Electrolyte Buffer reagent stored unopened at room temperature is stable until the expiration date printed on the bottle label. Once opened, the reagent is stable at room temperature for 30 days, unless the expiration date is exceeded. 3.For any electrolyte reagents frozen in transit, warm to room temperature, and mix thoroughly. Mix by gently inverting the bottle at least 20 times to redissolve salts back into solution. ISE Electrolyte Buffer Reagent and ISE Electrolyte Reference Reagent storage location: CALIBRATION CALIBRATOR REQUIRED SYNCHRON Systems AQUA CAL 1, 2 and 3 CALIBRATOR PREPARATION No preparation is required. CALIBRATOR STORAGE AND STABILITY 1.If unopened, the calibrators should be stored at +2C to +8C until the expiration date printed on the calibrator bottle. Once opened, the calibrators are stable at room temperature for 30 days. 2.Repetitive refrigeration of the aqueous calibrators may facilitate crystal formation. Once removed from refrigerated storage, these calibrators should remain at room temperature. Calibrator storage location: CALIBRATION INFORMATION 1.The system must have a valid calibration in memory before controls or patient samples can be run. 2.Under typical operating conditions the NA assay must be calibrated every 24 hours or with each new bottle of reagent and also with certain parts replacement or maintenance procedures, as defined in the SYNCHRON LX Maintenance Manual and Instrument Log, or the UniCel DxC 600/800 System Instructions for Use (IFU) manual. 3.For detailed calibration instructions, refer to the SYNCHRON LX Operations Manual, or the UniCel DxC 600/800 System Instructions For Use (IFU) manual. 4.The system will automatically perform checks on the calibration and produce data at the end of calibration. In the event of a failed calibration, the data will be printed with error codes and the system will alert the operator of the failure. For information on error codes, refer to the SYNCHRON LX Diagnostics and Troubleshooting Manual, or the UniCel DxC 600/800 System Instructions For Use (IFU) manual. TRACEABILITY For Traceability information refer to the Calibrator instructions for use. QUALITY CONTROL At least two levels of control material should be analyzed daily. In addition, these controls should be run with each new calibration, with each new bottle of reagent, and after specific maintenance or troubleshooting procedures as detailed in the appropriate system manual. More frequent use of controls or the use of additional controls is left to the discretion of the user based on good laboratory practices or laboratory accreditation requirements and applicable laws. The following controls should be prepared and used in accordance with the package inserts. Discrepant quality control results should be evaluated by your facility. NOTICE Do not use controls containing diethylamine HCl. Table 1 Quality Control Material CONTROL NAMESAMPLE TYPESTORAGETESTING PROCEDURE(S) 1.If necessary, load the reagent onto the system. 2.After reagent load is completed, calibration is required. 3.Program samples and controls for analysis. 4.After loading samples and controls onto the system, follow the protocols for system operations. For detailed testing procedures, refer to the SYNCHRON LX Operations Manual, or the UniCel DxC 600/800 System Instructions For Use (IFU) manual. CALCULATIONS The SYNCHRON System(s) performs all calculations internally to produce the final reported result. The system will calculate the final result for sample dilutions made by the operator when the dilution factor is entered into the system during sample programming. REPORTING RESULTS Equivalency between the SYNCHRON LX and UniCel DxC 600/800 Systems has been established. Chemistry results between these systems are in agreement and data from representative systems may be shown. REFERENCE INTERVALS Each laboratory should establish its own reference intervals based upon its patient population. The following reference intervals were taken from literature and a study performed on SYNCHRON Systems.REF "bibA1852930" \f \h \n 4 Table 2 Reference intervals RANGESAMPLE TYPECONVENTIONAL UNITSS.I. UNITSLiteratureSerum or Plasma136 145 mmol/L136 145 mmol/LUrine (timed)40 220 mmol/24 hrs40 220 mmol/24 hrsSYNCHRONSerum or Plasma136 144 mmol/L136 144 mmol/L RANGESAMPLE TYPECONVENTIONAL UNITSS.I. UNITSLaboratoryRefer to References (REF "bibA1852931" \f \h \n 5, REF "bibA1852915" \f \h \n 6, REF "bibA18529178" \f \h \n 7) for guidelines on establishing laboratory-specific reference intervals. Additional reporting information as designated by this laboratory: PROCEDURAL NOTES ANTICOAGULANT TEST RESULTS 1.If plasma is the sample of choice, the following anticoagulants were found to be compatible with this method based on a study of 20 healthy volunteers: Table 3 Compatible Anticoagulants ANTICOAGULANTLEVEL TESTED FOR IN VITRO INTERFERENCEAVERAGE PLASMA-SERUM BIAS (mmol/L)Ammonium Heparin14 Units/mLNSIaLithium Heparin14 Units/mLNSISodium Heparin14 Units/mLNSI2.The following anticoagulants were found to be incompatible with this method: Table 4 Incompatible Anticoagulants ANTICOAGULANTLEVEL TESTED FOR IN VITRO INTERFERENCEPLASMA-SERUM BIAS (mmol/L)bPotassium Oxalate/Sodium Fluoride2.0 / 2.5 mg/mL+3.5LIMITATIONS 1.If urine samples are cloudy or turbid, it is recommended that they be centrifuged before transfer to a sample cup. 2.For each sodium measurement, the potassium concentration is used in the calculation of the sodium concentration. If the potassium chemistry is not calibrated, or the potassium value is out of range for the sample type, the sodium value will be suppressed for urine samples. Serum samples will use a nominal value for potassium. INTERFERENCES 1.The following substances were tested for interference with this methodology: Table 5 Interferences SUBSTANCESOURCELEVEL TESTEDOBSERVED EFFECTcBilirubin (unconjugated)Bovine30 mg/dLNSIdHemoglobinRBC hemolysate500 mg/dLNSILipemiaIntralipide500 mg/dLNSILithiumLithium Acetoacetic Acid20 mmol/L+5 mmol/LBenzalkonium chlorideNAf0.5 mg/dL-2 mmol/LMethylbenzethonium ChlorideNA0.2 mg/dL-2 mmol/L2.Lipemic samples with visual turbidity >3+, or with a Lipemia Serum Index >10, should be ultracentrifuged and the analysis performed on the infranate. 3.Refer to References (REF "bibA1852933" \f \h \n 8,REF "bibA18529158" \f \h \n 9,REF "bibA1852935" \f \h \n 10) for other interferences caused by drugs, disease and preanalytical variables. PERFORMANCE CHARACTERISTICS Analytic Range The SYNCHRON System(s) method for the determination of this analyte provides the following analytical range: Table 6 Analytical Range SAMPLE TYPECONVENTIONAL UNITSS.I. UNITSSerum or Plasma100 200 mmol/L100 200 mmol/LUrine10 300 mmol/L10 300 mmol/LSamples with concentrations exceeding the high end of the analytical range should be diluted with deionized water and reanalyzed. REPORTABLE RANGE (as determined on site): Table 7 Reportable Range SAMPLE TYPECONVENTIONAL UNITSS.I. UNITSSENSITIVITY Sensitivity is defined as the lowest measurable concentration which can be distinguished from zero with 95% confidence. Sensitivity for NA determination is 100 mmol/L for serum or plasma, and 10 mmol/L for urine. EQUIVALENCY Equivalency was assessed by Deming regression analysis of patient samples to accepted clinical methods. Serum or Plasma (in the range of 100.1 to 190.8 mmol/L):Y (SYNCHRON LX Systems)= 0.979X + 2.20N= 236MEAN (SYNCHRON LX Systems)= 141.1MEAN (SYNCHRON CX Systems)= 141.9CORRELATION COEFFICIENT (r)= 0.992 Urine (in the range of 17.9 to 265.2 mmol/L):Y (SYNCHRON LX Systems)= 1.005X + 0.48N= 100MEAN (SYNCHRON LX Systems)= 113.9MEAN (SYNCHRON CX Systems)= 112.8CORRELATION COEFFICIENT (r)= 0.999 Serum or Plasma (in the range of 104 to 200 mmol/L):Y (UniCel DxC Systems)= 1.012X - 0.07N= 149MEAN (UniCel DxC Systems)= 141.7MEAN (SYNCHRON LX Systems)= 140.7CORRELATION COEFFICIENT (r)= 0.997 Urine (in the range of 18 to 294 mmol/L):Y (UniCel DxC Systems)= 1.017X - 1.57N= 110MEAN (UniCel DxC Systems)= 125.3MEAN (SYNCHRON LX Systems)= 124.8CORRELATION COEFFICIENT (r)= 0.999Refer to References (REF "bibA18529264" \f \h \n 11) for guidelines on performing equivalency testing. PRECISION A properly operating SYNCHRON System(s) should exhibit imprecision values less than or equal to the maximum performance limits in the table below. Maximum performance limits were derived by an examination of the imprecision of various methods, proficiency test summaries, and literature sources. Table 8 Maximum Performance Limits TYPE OF PRECISIONSAMPLE TYPE1 SDCHANGEOVER VALUEg% CVmmol/Lmmol/LWithin-runSerum/Plasma1.0100.01.0Urine2.050.04.0TotalSerum/Plasma1.5100.01.5Urine3.050.06.0Comparative performance data for the SYNCHRON LX System evaluated using the NCCLS Approved Guideline EP5-A appears in the table below.REF "bibA18529258" \f \h \n 12 Each laboratory should characterize their own instrument performance for comparison purposes. Table 9 NCCLS EP5-A Precision Estimate Method TYPE OF IMPRECISIONSAMPLE TYPENo. SystemsNo. Data PointshTest Mean Value (mmol/L)EP5-A Calculated Point EstimatesSD%CVWithin-runSerumControl 1180109.90.720.7SerumControl 2180156.20.800.5UrineControl 118084.50.550.7UrineControl 2180165.91.270.8TotalSerumControl 1180109.90.980.9SerumControl 2180156.21.170.8UrineControl 118084.50.911.1UrineControl 2180165.91.611.0NOTICE These degrees of precision and equivalency were obtained in typical testing procedures on a SYNCHRON LX System and are not intended to represent the performance specifications for this reagent. ADDITIONAL INFORMATION For more detailed information on SYNCHRON LX Systems or UniCel DxC Systems, refer to the appropriate system manual. SHIPPING DAMAGE If damaged product is received, notify your Beckman Coulter Clinical Support Center. REFERENCES Tietz, N. W., "Specimen Collection and Processing; Sources of Biological Variation", Textbook of Clinical Chemistry, 2nd Edition, W. B. Saunders, Philadelphia, PA (1994). National Committee for Clinical Laboratory Standards, Procedures for the Handling and Processing of Blood Specimens, Approved Guideline, NCCLS publication H18-A, Villanova, PA (1990). National Committee for Clinical Laboratory Standards, Routine Urinalysis and Collection, Transportation and Preservation of Urine Specimens, Tentative Guideline, NCCLS publication GP16-T, Villanova, PA (1992). Tietz, N. W., Clinical Guide to Laboratory Tests, 3rd Edition, W. B. Saunders, Philadelphia, PA (1995). Tietz, N. W., ed., Fundamentals of Clinical Chemistry, 3rd Edition, W. B. Saunders, Philadelphia, PA (1987). National Committee for Clinical Laboratory Standards, How to Define, Determine, and Utilize Reference Intervals in the Clinical Laboratory, Approved Guideline, NCCLS publication C28-A, Villanova, PA (1995). Henry, J. B., Clinical Diagnosis and Management by Laboratory Methods, 18th Edition, W. B. Saunders Company, Philadelphia, PA (1991). Young, D. S., Effects of Drugs on Clinical Laboratory Tests, 4th Edition, AACC Press, Washington, D. C. (1995). Friedman, R. B., Young, D. S.,Effects of Disease on Clinical Laboratory Tests, 3rd Edition, AACC Press, Washington, D.C. (1997). Young, D. S., Effects of Preanalytical Variables on Clinical Laboratory Tests, 2nd Edition, AACC Press, Washington, D. C. (1997). National Committee for Clinical Laboratory Standards, Method Comparison and Bias Estimation Using Patient Samples, Approved Guideline, NCCLS publication EP9-A, Villanova, PA (1995). National Committee for Clinical Laboratory Standards, Evaluation of Precision Performance of Clinical Chemistry Devices, Approved Guideline, Vol. 19, No. 2, NCCLS publication EP5-A, Villanova, PA (1999). Beckman Coulter Ireland Inc., Mervue Business Park, Mervue, Galway, Ireland (353 91 774068) Beckman Coulter, Inc., 250 South Kraemer Blvd., Brea, CA 92821 ENDNOTES a NSI = No Significant Interference (within 2.0 mmol/L or 2%). b Bias is based on worst case instead of average. Plus (+) or minus (-) signs in this column signify positive or negative bias. c Plus (+) or minus (-) signs in this column signify positive or negative interference. d NSI = No Significant Interference (within 2 mmol/L or 2%). e Intralipid is a registered trademark of KabiVitrum, Inc., Clayton, NC 27250. f NA = Not applicable. g When the mean of the test precision data is less than or equal to the changeover value, compare the test SD to the SD guideline given above to determine the acceptability of the precision testing. When the mean of the test precision data is greater than the changeover value, compare the test % CV to the guideline given above to determine acceptability. Changeover value = (SD guideline/CV guideline) x 100. h The point estimate is based on the pooled data from one system, run for twenty days, two runs per day, two observations per run on an instrument operated and maintained according to the manufacturer's instructions.     NA A18529AF EN  SAVEDATE \@ "MM/dd/yyyy" \* MERGEFORMAT 11/27/2000  PAGE \* MERGEFORMAT 1 /  NUMPAGES \* MERGEFORMAT 13   mub c u v u v   %&'()&'BCDEꝓrꝓ`"j hshsH*U^JjhshsH*U^J"j hshsH*U^JhshsH*^Jjhshs0JU^J!jhshsOJQJU^Jhshs0J^Jhshs5^Jhshs6^Jhshs0J5CJ^Jhshs^JhshsOJQJ^J%125<GR]hisqUkd$$Ifl40xxx(#4x4lalf4yts}$Ify$Ift$Ifz$Ifx$If$If p-DM UU]WJ $$Ifa$$Ifkdk$$Ifl44\# #  (#4x4lalf4p yts$$$Ifa$gds $$Ifgdsq{kd.$$Ifl4\# #  (#4x4lalf4yts $$Ifa$$If~q~q $$Ifa$$If{kd$$Ifl4\# #  (#4x4lalf4yts~q~q $$Ifa$$If{kd$$Ifl4\# #  (#4x4lalf4yts! 7 ] i K d ~~~~~v~$a$gds{kdG$$Ifl4\# #  (#4x4lalf4yts -LG-2[qzkd $$Ifl4"(# t0(#644x4laf4p yts $Ifgds~I EF  ()*+,-./01456QR!!!!!###:%Ͻϫ蠑蠑蠑蠑腠z蠑z蠑hshs0J^Jhshs5CJ^JhshsCJOJQJ^JhshsCJ^J"jr hshsH*U^J"j hshsH*U^JhshsH*^Jjhshs0JU^Jhshs^JjhshsH*U^J+[456Juzkd $$Ifl4"(# t0(#644x4laf4p yts $Ifgds~w $Ifgds~zkd1 $$Ifl4"(# t0(#644x4laf4p yts5U~||||vi $$Ifa$$Ifzkd $$Ifl4"(# t0(#644x4laf4p yts xre $$Ifa$$Ifzkdu$$Ifl4F#wx(#6    4x4lalf4pyts $$Ifa$4=r $$Ifa$$Ifzkd,$$Ifl4F#wx(#6    4x4lalf4pyts=>@[dr $$Ifa$$Ifzkd$$Ifl4F# x(#6    4x4lalf4pytsdegir $$Ifa$$Ifzkd$$Ifl4F# x(#6    4x4lalf4pytsvv $$IfgdszkdI$$Ifl4F# x(#6    4x4lalf4pyts*bkd$$Ifl40#xx(#64x4lalf4pyts$Iflkd$$Ifl440#xx  (#64x4lalf4pyts5bkd$$Ifl40#xx(#64x4lalf4pytsbkd$$Ifl40#xx(#64x4lalf4pyts$If&'2>?5bkd$$Ifl40#xx(#64x4lalf4pytsbkd%$$Ifl40#xx(#64x4lalf4pyts$If?ISTdpq5bkd$$Ifl40#xx(#64x4lalf4pytsbkd/$$Ifl40#xx(#64x4lalf4pyts$Ifqz $$Ifa$bkd9$$Ifl40#xx(#64x4lalf4pyts$IfIo R!!! $Ifgds~Ibkd$$Ifl40#(#64x4lalf4pyts!!!!!"$"E" ####~~||zq $Ifgds~Izkdc$$Ifl4"(# t0(#644x4laf4p yts ###`$%@&''4(D(****~|~~zzVIzkd$$Ifl4"(# t0(#644x4laf4p yts :%_%%%%%&1&p''''+'+(+3+4+;+g+,,,-+-,-///////000'0(0:0;0E011 1 111+1,161S1h1i1컱jhshsU^JjhshsH*U^J"jShshsH*U^JhshsH*^Jjhshs0JU^Jhshs0J^JhshsCJ^Jhshs5CJ^Jhshs^Jhshs0J^J3*+(+4+<+=+?+A+C+ysff $$Ifa$$Ifqkd$$Ifl44F d#O O O (#6    4x4lalf4p yts$$$Ifa$gdsC+D+F+H+J+ $$Ifa$$Ifikd;$$Ifl4F d#O O O (#6    4x4lalf4ytsJ+K+M+O+Q+ $$Ifa$$Ifikd$$Ifl4F d#O O O (#6    4x4lalf4ytsQ+R+T+V+X+ $$Ifa$$IfikdC$$Ifl4F d#O O O (#6    4x4lalf4ytsX+Y+[+]+_+ $$Ifa$$Ifikd$$Ifl4F d#O O O (#6    4x4lalf4yts_+`+b+d+f+ $$Ifa$$IfikdK$$Ifl4F d#O O O (#6    4x4lalf4ytsf+g+|+++,,--&.8..//0Iikd$$Ifl4F d#O O O (#6    4x4lalf4yts00(0;0F0G0S0d0v00d^$Ifkd$$Ifl44\R#  (#64x4lalf4p yts $$Ifa$ 000000uuuu $$Ifa$|kdz$$Ifl4\R#`(#64x4lalf4yts000001|ooo $$Ifa$$If|kd $$Ifl4\R# (#64x4lalf4yts111 11,171ssss $$Ifa$|kd$$Ifl4\R#(#64x4lalf4yts7181D1F1H1J1qk^^^ $$Ifa$$Ifkd`$$Ifl44\R#  (#64x4lalf4p ytsJ1K1L1N1P1R1uuuu $$Ifa$|kd $$Ifl4\R#`(#64x4lalf4ytsR1S12Z2[2~u $Ifgds~|kd $$Ifl4\R# (#64x4lalf4ytsi11111111111111111111Z2[2\2F3S3T3z3{3333 444444445S7\7]7c7d7p7q7777777^8hshs0JCJ^Jhshs5CJ^JhshsCJOJQJ^JhshsCJ^JjZ"hshsU^Jj!hshsU^JjhshsU^Jjh!hshsU^Jhshs^J5[2\2m22$3F3T3{33~|jjj$$$Ifa$gdsIzkd"$$Ifl4"(# t0(#644x4laf4p yts33333zq $Ifgds $$Ifa$$Ifqkdw#$$Ifl44F4 (##e e (#6    4x4lalf4p yts33333 $$Ifa$$Ifikd$$$Ifl4F4 (##e e (#6    4x4lalf4yts3334 4 $$Ifa$$Ifikd$$$Ifl4F4 (##e e (#6    4x4lalf4yts 4 4]44444t $$Ifgds$$$Ifa$gdsIikd=%$$Ifl4F4 (##e e (#6    4x4lalf4yts44455zz $$Ifa$$Ifqkd%$$Ifl44F4 (##e e (#6    4x4lalf4p yts555566=7S7]7d7q77}}}r $$Ifgds$$$Ifa$gdsIikdq&$$Ifl4F4 (##e e (#6    4x4lalf4yts 777777ztgg^ $Ifgds $$Ifa$$Ifkd'$$Ifl44\> }#,V (#64x4lalf4p yts777777|ooo $$Ifa$$If|kd'$$Ifl4\> }#,V (#64x4lalf4yts77778 8|sff $$Ifa$ $Ifgds$If|kd($$Ifl4\> }#,V (#64x4lalf4yts 8 88-888C8|ooo $$Ifa$$If|kd5)$$Ifl4\> }#,V (#64x4lalf4ytsC8D8[8`8k8v8|sff $$Ifa$ $Ifgds$If|kd)$$Ifl4\> }#,V (#64x4lalf4yts^8_88b9c9~9999999999999999999M:N:::::::S;<#<$<6<7<A<X<==>>>???l@m@@KA`AaA}A߲ߢߗߋߋߋߋߋߋhshs5CJ^Jhshs0J^Jj-hshsU^Jj,hshsU^Jj ,hshsU^JjhshsU^Jhshs^JhshsCJ^Jhshs0JCJ^J6v8w88888|ooo $$Ifa$$If|kd*$$Ifl4\> }#,V (#64x4lalf4yts88I9:2:A::::::~|zxfff$$$Ifa$gdsI|kdW+$$Ifl4\> }#,V (#64x4lalf4yts ::;;(;zz $$Ifa$$Ifqkdz-$$Ifl44F d#O O O (#6    4x4lalf4p yts(;);0;A;R; $$Ifa$$Ifikd.$$Ifl4F d#O O O (#6    4x4lalf4ytsR;S;;;<$<7<B<}}}$$$Ifa$gdsikd.$$Ifl4F d#O O O (#6    4x4lalf4ytsB<C<E<G<I<zz $$Ifa$$Ifqkd/$$Ifl44F d#O O O (#6    4x4lalf4p ytsI<J<L<N<P< $$Ifa$$Ifikd/$$Ifl4F d#O O O (#6    4x4lalf4ytsP<Q<S<U<W< $$Ifa$$Ifikd.0$$Ifl4F d#O O O (#6    4x4lalf4ytsW<X<d<:=F=====tt$$$Ifa$gds $$Ifgdsikd0$$Ifl4F d#O O O (#6    4x4lalf4yts===>>}}}$If{kd61$$Ifl44F#(#6    4x4lalf4pyts>>>>#>$Ifzkd1$$Ifl4Fd# O (#6    4x4lalf4pyts#>$>&>B>K>$Ifzkd2$$Ifl4Fd# O (#6    4x4lalf4pytsK>L>N>j>s>$IfzkdV3$$Ifl4Fd# O (#6    4x4lalf4pytss>t>v>>>$Ifzkd 4$$Ifl4Fd# O (#6    4x4lalf4pyts>>>>>>xff$$$Ifa$gds $$Ifgdszkd4$$Ifl4Fd# O (#6    4x4lalf4pyts>>>>>}}}$If{kdo5$$Ifl44F#(#6    4x4lalf4pyts>>>??$Ifzkd)6$$Ifl4Fd# O (#6    4x4lalf4pyts? ? ?'?0?$Ifzkd6$$Ifl4Fd# O (#6    4x4lalf4pyts0?1?3?O?X?$Ifzkd7$$Ifl4Fd# O (#6    4x4lalf4pytsX?Y?[?x??$IfzkdB8$$Ifl4Fd# O (#6    4x4lalf4pyts??????xff$$$Ifa$gds $$Ifgdszkd8$$Ifl4Fd# O (#6    4x4lalf4pyts?????}}}$If{kd9$$Ifl44F#(#6    4x4lalf4pyts?????$Ifzkdb:$$Ifl4Fd# O (#6    4x4lalf4pyts???@@$Ifzkd;$$Ifl4Fd# O (#6    4x4lalf4pyts@@@9@B@$Ifzkd;$$Ifl4Fd# O (#6    4x4lalf4pytsB@C@E@b@k@$Ifzkd{<$$Ifl4Fd# O (#6    4x4lalf4pytsk@l@m@@@@xff$$$Ifa$gds $$Ifgdszkd.=$$Ifl4Fd# O (#6    4x4lalf4pyts@@@@@}}}$If{kd=$$Ifl44F#(#6    4x4lalf4pyts@@@@@$Ifzkd>$$Ifl4Fd# O (#6    4x4lalf4pyts@@@@@$IfzkdN?$$Ifl4Fd# O (#6    4x4lalf4pyts@@@A!A$Ifzkd@$$Ifl4Fd# O (#6    4x4lalf4pyts!A"A$AAAJA$Ifzkd@$$Ifl4Fd# O (#6    4x4lalf4pytsJAKAAAB CC*C/CACFCrrrir $Ifgds $$Ifa$zkdgA$$Ifl4Fd# O (#6    4x4lalf4pyts }A~AAAAAA CCC)C*C.C/C?C@CACECICOCPCVCCdDeDDDDDDE'E(E3E5E@EAEPEQEREjEkEEEE···ª···ٛp···ª··jhshsH*U^J"jGhshsH*U^JhshsH*^Jjhshs0JU^Jhshs0JCJ^JhshsCJ^Jhshs5CJ^Jhshs0J^Jhshs^JjhshsU^JjBhshsU^J,FCGCHCICPCWCXC^QQQQQ $$Ifa$kdB$$Ifl44rt f#``ttt`  (#64x4lalf4p ytsXCYCeCsCxCCCgaTTTT $$Ifa$$IfkdvC$$Ifl44rt f#  ttt (#64x4lalf4p ytsCCCCCCCobbbbb $$Ifa$kdD$$Ifl4rt f#`ttt(#64x4lalf4ytsCCCCCCCoi\\\\ $$Ifa$$Ifkd\E$$Ifl4rt f# ttt(#64x4lalf4ytsCCCCCCCobbbbb $$Ifa$kdIF$$Ifl4rt f#`ttt(#64x4lalf4ytsCCDE(E4E5EAEREkEomk^^^^U^ $Ifgds $$Ifa$kdF$$Ifl4rt f# ttt(#64x4lalf4yts kEEE $$Ifa$EEE% $$Ifa$kdfH$$Ifl44ִfgLM#`abg`]`]`   (#6    4x4lalf4p ytsEEEEEEEE $$Ifa$EEEGGGG.ILIIIrJJK>KKKLmLLLFMsMMM7NvNNOOO-P.PPPUUUUUUUU3U4U^U_UiUjUkUlUUUUUUUUhsmHnHuhsjhsUjiWhshsU^Jj\ThshsU^Jhshs0J^JhshsH*^Jhshs0J^Jhshs^Jhshs5CJ^JhshsCJ^J9EEE.($IfkdI$$Ifl44ִfgL# !"g ] ] (#6    4x4lalf4p ytsEEEEEEEE $$Ifa$EEEEE6))) $$Ifa$kd$K$$Ifl4ִf1 L#`] ]](#6    4x4lalf4ytsEEEEEF $$Ifa$FFF FF6))) $$Ifa$kd!L$$Ifl4ִf1 L# ] ]](#6    4x4lalf4ytsFFF!F'F,F $$Ifa$,F-F.F5F@F6))) $$Ifa$kdVM$$Ifl4ִf1 L# ] ]](#6    4x4lalf4yts@FCFGFNFTFYF $$Ifa$YFZFaFhF60# $$Ifa$$IfkdN$$Ifl4ִf1 L# ] ]](#6    4x4lalf4ytshFsFvFzFFFF $$Ifa$FFFFF6))) $$Ifa$kdO$$Ifl4ִf1 L#`] ]](#6    4x4lalf4ytsFFFFFF $$Ifa$FFFFF6))) $$Ifa$kdP$$Ifl4ִf1 L# ] ]](#6    4x4lalf4ytsFFFFFF $$Ifa$FFFFF6))) $$Ifa$kdQ$$Ifl4ִf1 L# ] ]](#6    4x4lalf4ytsFFGG GG $$Ifa$GGGGGiH64420Vkd'S$$Ifl4ִf1 L# ] ]](#6    4x4lalf4ytsiHyHHHInW3UoG F7GPNG  IHDR0@ `PLTE@K -0<`iPZpxʐְ```ࠠаPPPppp @@@CKqbKGDH cmPPJCmp0712Hs|IDAThCX s8 ;.l BSoj8uzKۊӇuAG_UOC*9VyԄXYeixj ZgT{jfa|S/zZKTqGP:.pGÎq;5 j%{"\M=ZDi;C?G CLmH>,SB1ځ a>cEcokwǾI5h@#RsQvU۞Dqς{`j9jB[kPJb4IENDB`yDyK  bibA1852928yDyK  bibA1852914yDyK  bibA1852914{DyK  bibA18529278$$If!vh5(##v(#:Vl4 t0(#65(#4xf4p yts$$If!vh5(##v(#:Vl4 t0(#65(#4xf4p yts$$If!vh5(##v(#:Vl4 t0(#65(#4xf4p yts$$If!vh5(##v(#:Vl4 t0(#65(#4xf4p yts$$If`!vh555#v#v#v$V:V l4(#655w5x44xalf4pyts$$If`!vh555#v#v#v$V:V l4(#655w5x44xalf4pyts$$If`!vh555#v#v#v:V l4(#655 5x44xalf4pyts$$If`!vh555#v#v#v:V l4(#655 5x44xalf4pyts$$If`!vh555#v#v#v:V l4(#655 5x44xalf4pyts$$If`!vh55#v:V l44  (#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55#v:V l4(#65x44xalf4pyts$$If`!vh55'##v#v'#$V:V l4(#655/ 44xalf4pyts$$If!vh5(##v(#:Vl4 t0(#65(#4xf4p yts$$If!vh5(##v(#:Vl4 t0(#65(#4xf4p yts$$If`!vh5 5 5 #v :V l44(#65O / 44xalf4p yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4ytsyDyK  bibA1852930$$If`!vh5555#v:V l44  (#65/ 44xalf4p yts$$If`!vh5555#v:V l4(#6+5/ 44xalf4yts$$If`!vh5555#v:V l4(#6+5/ / / / / 44xalf4yts$$If`!vh5555#v:V l4(#65/ 44xalf4yts$$If`!vh5555#v:V l44  (#65/ 44xalf4p yts$$If`!vh5555#v:V l4(#6+5/ 44xalf4yts$$If`!vh5555#v:V l4(#6+5/ / / / / 44xalf4ytsyDyK  bibA1852931yDyK  bibA1852915{DyK  bibA18529178$$If!vh5(##v(#:Vl4 t0(#65(#4xf4p yts$$If`!vh5@ 5 5 #v@ #v :V l44(#65#5e / 44xalf4p yts$$If`!vh5@ 5 5 #v@ #v :V l4(#65#5e / 44xalf4yts$$If`!vh5@ 5 5 #v@ #v :V l4(#65#5e / 44xalf4yts$$If`!vh5@ 5 5 #v@ #v :V l4(#65#5e / 44xalf4yts$$If`!vh5@ 5 5 #v@ #v :V l44(#65#5e / 44xalf4p yts$$If`!vh5@ 5 5 #v@ #v :V l4(#65#5e / 44xalf4yts$$If`!vh5J 5 55#vJ #v #v#v:V l44(#65,5V 55/ 44xalf4p yts$$If`!vh5J 5 55#vJ #v #v#v:V l4(#65,5V 55/ 44xalf4yts$$If`!vh5J 5 55#vJ #v #v#v:V l4(#65,5V 55/ 44xalf4yts$$If`!vh5J 5 55#vJ #v #v#v:V l4(#65,5V 55/ 44xalf4yts$$If`!vh5J 5 55#vJ #v #v#v:V l4(#65,5V 55/ 44xalf4yts$$If`!vh5J 5 55#vJ #v #v#v:V l4(#65,5V 55/ 44xalf4yts$$If`!vh5J 5 55#vJ #v #v#v:V l4(#65,5V 55/ 44xalf4ytsyDyK  bibA1852933{DyK  bibA18529158yDyK  bibA1852935$$If`!vh5 5 5 #v :V l44(#65O / 44xalf4p yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l44(#65O / 44xalf4p yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh5 5 5 #v :V l4(#65O / 44xalf4yts$$If`!vh555&##v#v&#$V:V l44(#655/ 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555&##v#v&#$V:V l44(#655/ 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555&##v#v&#$V:V l44(#655/ 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555&##v#v&#$V:V l44(#655/ 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts$$If`!vh555 #v#v#v :V l4(#655 5O 44xalf4pyts{DyK  bibA18529264$$If`!vh55y5y5y5=#v#vy#v=:V l44  (#6+++55t5/ 44xalf4p yts/$$If`!vh55y5y5y5=#v#vy#v=:V l44(#6+++55t5/ / / / / / / / 44xalf4p yts$$If`!vh55y5y5y5=#v#vy#v=:V l4(#6+55t5/ 44xalf4yts$$If`!vh55y5y5y5=#v#vy#v=:V l4(#6+55t5/ / / / / 44xalf4yts$$If`!vh55y5y5y5=#v#vy#v=:V l4(#6+55t5/ 44xalf4yts$$If`!vh55y5y5y5=#v#vy#v=:V l4(#6+55t5/ / / / / 44xalf4yts{DyK  bibA18529258L$$If`!vh5r55y 55555#vr#v#vy #v#v#v#v#v$V$V:V l44  (#6++++++555g5]555 / 44xalf4p ytsn$$If`!vh5r55y 5555h5h#vr#v#vy #v#v#v#vh$V:V l44(#6++++++555g5]55/ / / / / / 44xalf4p yts$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ 44xalf4yts3$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ / / / / 44xalf4yts3$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ / / / / 44xalf4yts3$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ / / / / 44xalf4yts$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ 44xalf4yts3$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ / / / / 44xalf4yts3$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ / / / / 44xalf4yts3$$If`!vh5r555555h5h#vr#v#v#v#v#v#vh:V l4(#6+55]5 5]55/ / / / / 44xalf4yts DdJ  C &AEC_REPboYQ/.h`,pKTnCYQ/.h`,pPNG  IHDRQ@`PLTE000 ```PPPppp@@@d5tRNS%bbKGD , cmPPJCmp0712HsKIDATHKݲ 'gA#Les@6r R>y&0(%#Xב򤜛 ',9\ɓ UQ#2Qw R\J=2@DC=ƭ&j`JC-Qz9Ԉ&p-(⯙OM KZw͂HT(.1 $FFή4^qHLgtqP&5zj52tr'[gf3j()vyכag1&gθG fV2=Atgmjq21Mg( -ukw.?w:>0zWO4IENDB`DdhV   C 2AManufactd-bybLh߄$eDHs(Wn h߄$eDHsPNG  IHDRRe0PLTE ```ppp@@@Vd tRNSSOxbKGDޕz cmPPJCmp0712Om`IDAT(1@0DѨ%^ &6A&1r?'6LH}lAFd t:A=`$lEH>MjyIENDB`@`@ sNormalCJ_HaJmH sH tH Z`Z s Heading 1$$@&5CJKH\aJmH sH J`J s Heading 2$x@&5\mH sH J`J s Heading 3$<@&5\^JaJF`F s Heading 4$<@& 5\aJJ`J s Heading 5$<@& 5\]aJB`B s Heading 6 $$@& 5\aJ@`@ s Heading 7$<@&6B`B s Heading 8 $<@& 56]H `H s Heading 9 $<@& 5^JaJDA`D sDefault Paragraph FontVi@V  Table Normal :V 44 la (k`(sNo List pop s3colJ ,p@ P !$`' -DM ^ QJBoB s 3col-indent p^ `p\o\ s BaseArial10)B*OJPJQJ^J_HmH phsH tH T" Block TextX 8` p@ P !$`'x-D]^CJB*zB2z Body TextFx-D 8` p@ P !$`'CJB*PB Body Text 2Ldx-D 8` p@ P !$`'CJB*~QR~ Body Text 3Fx-D 8` p@ P !$`'CJB*Mb Body Text First IndentP 8` p@ P !$`'x-D`CJB*Nr Body Text First Indent 2X 8` p@ P !$`'hjx-D^h`jCJB*C Body Text IndentP 8` p@ P !$`'hx-D^hCJB*R Body Text Indent 2V 8` p@ P !$`'hdx-D^hCJB*S Body Text Indent 3P 8` p@ P !$`'hx-D^hCJB*/ sCAUTIONj$$$x$d%d&d'dNOPQ]^a$B*OJQJ\^Jph8"`8 sCaption xx5\|?| ClosingL 8` p@ P !$`'-D^CJB*< < s Comment TextOJQJlLl DateB-D 8` p@ P !$`'CJB*Y  Document MapB -D 8` p@ P !$`' OJCJB*+  s Endnote TextB! ,p@ P !$`'-DM B*OJQJaJph<o< sEndnotes "$1$5>*Ro2R s EndnotesJA #$5>*OJPJQJnHtH$B Envelope AddressL$ 8` p@ P !$`'@ -D^@ OJCJB*%R Envelope ReturnB%-D 8` p@ P !$`' OJCJB*< `b< sFooter& $]CJ8oar8 s FooterLine ' $N`N s Footnote Text(^`mH sH hoh sFootnotesLastPage#)$$h<<^h`a$mH sH VoV sFootnotesLastPageAsian* B*^Jph4`4 sHeader + !FoaF sHeading 6 Centered,$a$BoaB sHeading6Centered-$a$x x Index 1H. ,` @ P !!$`'-D^`CJB*x x Index 2H/ ,` @ P !!$`'-D^`CJB*x x Index 3H0 ,` @ P !!$`'-D^`CJB*x x Index 4H1 ,` @ P !!$`'-D^`CJB*x"x Index 5H2 ,` @ P !!$`'-D^`CJB*x2x Index 6H3 ,` @ P !!$`'-D^`CJB*xBx Index 7H4 ,` @ P !!$`'-D^`CJB*xRx Index 8H5 ,` @ P !!$`'-D^`CJB*xbx Index 9H6 ,` @ P !!$`'p-D^p`CJB*x!rx  Index Heading67-D ,` @ P !!$`'5OJCJB*0o0 s LangSpecOF8@o@ s LangSpecPAGE 9]CJr/r ListH: ,` @ P !!$`'h-D^h`CJB*v2v List 2H; ,` @ P !!$`'-D^`CJB*v3v List 3H< ,` @ P !!$`'8-D^8`CJB*v4v List 4H= ,` @ P !!$`'-D^`CJB*v5v List 5H> ,` @ P !!$`'-D^`CJB*\0`\ s List Bullet+?$ # p@ P !\6`\ s List Bullet 2(@$ p@ P 7` s List Bullet 3PA$$ ) p@ P !$`'-DM a$V8`"V s List Bullet 4"B$ pP 69`26 s List Bullet 5CDB List ContinueLD 7`  p@ P !$`'hx-D^hCJB*ER List Continue 2LE 7`  p@ P !$`'x-D^CJB*Fb List Continue 3LF 7`  p@ P !$`'8x-D^8CJB*Gr List Continue 4LG 7`  p@ P !$`'x-D^CJB*H List Continue 5LH 7`  p@ P !$`'x-D^CJB*d1`d s List Number+I$$ h@ <<^ `a$mH sH `:`` s List Number 2#J$$xx^`a$mH sH v;`v s List Number 3AK$$ # 8p@ P !8^8`a$j<`j s List Number 45L$  p@ jP ^`j=`j s List Number 55M$  p@   ^`bob sListItemHyphen+N$ # hp@ P `o` sListItemHyphen2(O$ p@ P fof sListItemHyphen3.P$ & 8p@ P J!^o^ sListItemHyphen4%Q$  p@ P `o"` sListItemHyphen5(R$ p@ P !<o2< s MYTESTSTYLES B*ph@-B@  Macro TextT-D OJCJB*XIRX Message HeaderU8-D^8` OJCJB*ob sNOTICEjV$$$x$d%d&d'dNOPQ]^a$%B*OJPJQJ_HmH phsH tH JrJ Normal IndentW-D^CJB*4O`4 s Note HeadingXXoX sOrderedlist-ParaY hh<<^h^JXoX sOrderlisted-ParaZ hh<<^h^J~Z~ Plain TextD[-D ;` hp@ P !$`' OJCJB*FoF s References\$$$h5CJzKz SalutationD]-D ;` hp@ P !$`'CJB*@ SignatureL^ ;` hp@ P !$`'-D^CJB*o sCStyle addressline + Left: -22 pt Right: -21 pt Before: 3 pt A... _$\H<<]\^Ha$mH sH boQb sStyle paraJust + 9 pt Bold `Am$ 5CJ\`oQ` sStyle paraJust + 9 pt Bold2aA 5CJ\oQ" s9Style paraJust + 9 pt Centered Before: 0 pt After: 0 pt b$a$m$ CJPJ^JoQ2 s:Style paraJust + 9 pt Centered Before: 0 pt After: 0 pt1 c$a$m$ CJPJ^JJB SubtitleQd$ ;` hp@ P !$`'<-Da$ OJCJB*.R  TOA HeadingHex-D ;` hp@ P !$`'5OJCJB*pbp TOC 1Df-D ;` hp@ P !$`'CJB*xrx TOC 2Lg ;` hp@ P !$`'-D^CJB*xx TOC 3Lh ;` hp@ P !$`'-D^CJB*xx TOC 4Li ;` hp@ P !$`'-D^CJB*xx TOC 5Lj ;` hp@ P !$`'-D^CJB*xx TOC 6Lk ;` hp@ P !$`'-D^CJB*xx TOC 7Ll ;` hp@ P !$`'-D^CJB*xx TOC 8Lm ;` hp@ P !$`'-D^CJB*xx TOC 9Ln ;` hp@ P !$`'-D^CJB*, Table of AuthoritiesTo ;` hp@ P !$`'-D^`CJB*# Table of FiguresTp ;` hp@ P !$`' -D^` CJB*N>`N sTitleq$<@&a$5CJKH\^JaJ /" sWARNINGjr$$$x$d %d &d 'd NOPQ]^a$5B* ^JphPo2P sacronym-footerplus s]CJ^JXoBX sacronym-headert$$]a$5CJ\aJ \oR\ s addressline#u$ p<<] ^pa$m$mH sH DobD s bibliomixed v$a$mH sH horh scallout?w ) p@ P !$`'-DM RoR schem-man-type-headerx$ 5CJ\>oA> schemical-headeryCJ LoL schempartnum-header z]CJDoD scopyright-header{CJaJ^o^ s formulaline)|$  -DM ^ a$5FoF s kit-header}$]a$5CJHoH s lab.notes ~$5:\mH sH vov smemberP$ ,p@ P !$`'-DM a$ZoZ snotetext-8pt-1$L^`La$CJaJXoX s notetext-list$\L^\`La$CJaJ8o"8 spara $<<mH sH 4o!24 sparaBold xxHoBH s paraCentered$$$((a$2o!R2 sparaJust$a$VoQbV sparaJust + 9 pt Bold Am$ 5CJ\^oQr^ sparaJust + 9 pt Centered$a$ CJPJ^JLoAL ssuperscript-table-para^JRoR ssystem-header-name$5CJ\aJ :o!: s table caption;^o^ stable-regular-list $TT(^T`Ta$BoB svitro$hxa$5\mH sH B' B sComment ReferenceCJaJLAL Default Paragraph FontCJB*2X2 Emphasis 6CJB*D*  D sEndnote Reference B*CJH*FV  F sFollowedHyperlink >*B* phL/! L sFootnote EntryB*CJH*OJQJph@& 1 @ sFootnote ReferenceH*6U A 6 s Hyperlink >*B*ph6(Q 6 Line NumberCJB*6)a 6 Page NumberCJB*.Wq . Strong 5CJB*(/B ( sbibrefH*2/ 2 s bibrefSuperH*0/ 0 s bolditalic68o 8 s booktitle 6CJH*S*2/ 2 schange q 4/ 4 semphasis B*CJOJB/ B sentrykey5CJH*OJPJQJS*^/ ^ s entrykey Char,5B*OJPJQJ_HaJmH phsH tH B/ B s subscriptH*OJPJQJmH sH Fo F s superscriptH*OJPJQJmH sH 0/! 0 ssymbol OJQJo(*/1 * sunbold5\j@C j s Table Grid7:V0MF  z z z z z z$z z z z z$ z"(=/5;@HMAO ?; 125<GR]hi!7]i Kd - L G -2[456J5U4=>@[degi&'2>?ISTdpqzIoR$E `@4 D """"#(#4#<#=#?#A#C#D#F#H#J#K#M#O#Q#R#T#V#X#Y#[#]#_#`#b#d#f#g#|###$$%%&&8&&''((((;(F(G(S(d(v(((((((((())) )),)7)8)D)F)H)J)L)N)P)R)S)*Z*[*\*m**$+F+T+{++++++++++++, , ,],,,,,,,-----..=/S/]/d/q///////////////0 0 00-080C0D0[0`0k0v0w000000I1222A222222233(3)303A3R3S3334$474B4C4E4G4I4J4L4N4P4Q4S4U4W4X4d4:5F555555566666#6$6&6B6K6L6N6j6s6t6v6666666666666677 7 7'7071737O7X7Y7[7x77777777777777777888898B8C8E8b8k8l8m8888888888888888889!9"9$9A9J9K999: ;;*;/;A;F;I;P;X;Y;e;s;x;;;;;;;;;;;;;;;;;;;;<=(=5=A=R=k======================>> >>>>!>'>,>->.>5>@>C>G>N>T>Y>Z>a>h>s>v>z>>>>>>>>>>>>>>>>>>>>>>>>?? ??????i@y@@@A@[degi&'2>?ISTdpqzIoR$E `@4 D """"#(#4#<#=#?#A#C#D#F#H#J#K#M#O#Q#R#T#V#X#Y#[#]#_#`#b#d#f#g#|###$$%%&&8&&''((((;(F(G(S(d(v((((((((((())) )),)7)8)D)F)H)J)K)L)N)P)R)S)*Z*[*\*m**$+F+T+{++++++++++++, , ,],,,,,,,-----..=/S/]/d/q///////////////0 0 00-080C0D0[0`0k0v0w000000I1222A222222233(3)303A3R3S3334$474B4C4E4G4I4J4L4N4P4Q4S4U4W4X4d4:5F555555566666#6$6&6B6K6L6N6j6s6t6v6666666666666677 7 7'7071737O7X7Y7[7x77777777777777777888898B8C8E8b8k8l8m8888888888888888889!9"9$9A9J9K999: ;;*;/;A;F;G;H;I;P;W;X;Y;e;s;x;;;;;;;;;;;;;;;;;;;;;;<=(=4=5=A=R=k=============================>>> >>>>!>'>,>->.>5>@>C>G>N>T>Y>Z>a>h>s>v>z>>>>>>>>>>>>>>>>>>>>>>>>>>>?? ??????i@y@@@A@[degi&'2>?ISTdpqzIoR$E `@4 D """"#(#4#<#=#?#A#C#D#F#H#J#K#M#O#Q#R#T#V#X#Y#[#]#_#`#b#d#f#g#|###$$%%&&8&&''((((;(F(G(S(d(v((((((((((())) )),)7)8)D)F)H)J)K)L)N)P)R)S)*Z*[*\*m**$+F+T+{++++++++++++, , ,],,,,,,,-----..=/S/]/d/q///////////////0 0 00-080C0D0[0`0k0v0w000000I1222A222222233(3)303A3R3S3334$474B4C4E4G4I4J4L4N4P4Q4S4U4W4X4d4:5F555555566666#6$6&6B6K6L6N6j6s6t6v6666666666666677 7 7'7071737O7X7Y7[7x77777777777777777888898B8C8E8b8k8l8m8888888888888888889!9"9$9A9J9K999: ;;*;/;A;F;G;H;I;P;W;X;Y;e;s;x;;;;;;;;;;;;;;;;;;;;;;<=(=4=5=A=R=k=============================>>> >>>>!>'>,>->.>5>@>C>G>N>T>Y>Z>a>h>s>v>z>>>>>>>>>>>>>>>>>>>>>>>>>>>?? ??????i@y@@@A#>K>s>>>>?0?X?????@B@k@@@@@!AJAFCXCCCCCkEEEEEEEFF,F@FYFhFFFFFFFGiHQUU,./012356789:;<=>?@ABCDFGHIJKLMNOPQRSUVWXYZ[\]^_`bcdefghijklmnopqrstuvwxyz{|}~U- & ( & C E )+.0'''h)))))))))b111111111`9~99d<<<M"MXZrtx! bibA1852928 bibA1852914 bibA18529278 bibA1852930 bibA1852931 bibA1852915 bibA18529178 bibA1852933 bibA18529158 bibA1852935 bibA18529264 bibA18529258@A'$"T\omwi~Sa_/T9h^`.^`.88^8`.^`. ^`OJQJo( ^`OJQJo( 88^8`OJQJo( ^`OJQJo(hh^h`. hh^h`OJQJo(h ^`hH.h ^`hH.h pLp^p`LhH.h @ @ ^@ `hH.h ^`hH.h L^`LhH.h ^`hH.h ^`hH.h PLP^P`LhH. ~}|a_/T         s2hi24564=>@[degi&'2>?ISTdpqzR""#(#4#<#=#?#A#C#D#F#H#J#K#M#O#Q#R#T#V#X#Y#[#]#_#`#b#d#f#g#'((((;(F(G(S(d(v((((((((((())) )),)7)8)D)F)H)J)K)L)N)P)R)S)*Z*[*\**$+F+T+{++++++++++++, , ,],,,,,,,---=/S/]/d/q///////////////0 0 00-080C0D0[0`0k0v0w000000A222222233(3)303A3R3S3334$474B4C4E4G4I4J4L4N4P4Q4S4U4W4X4:5F555555566666#6$6&6B6K6L6N6j6s6t6v6666666666666677 7 7'7071737O7X7Y7[7x77777777777777777888898B8C8E8b8k8l8m8888888888888888889!9"9$9A9J9K99: ;;*;/;A;F;G;H;I;P;W;X;Y;e;s;x;;;;;;;;;;;;;;;;;;;;;;<=(=4=5=A=R=k=============================>>> >>>>!>'>,>->.>5>@>C>G>N>T>Y>Z>a>h>s>v>z>>>>>>>>>>>>>>>>>>>>>>>>>>>?? ???M}0@`@{MP@UnknownGz Times New Roman5Symbol3& z ArialI& ??Arial Unicode MS5& zaTahomaK5   hMS Gothic-3 0000?5 z Courier New"HhhK&+ [A  [A d4$K$K 2QHP ?Ns2BCI8         Oh+'0P    $08@H Normal.dotBCI2Microsoft Office Word@@tX@jxE  [A՜.+,D՜.+,P  px  Beckman Coulter, Incp$K'  Title0x Code VersionDate ProcessedProcessing Time2009.03.25 | 16.038/26/2010 4:43:22 PM2.53 seconds  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefgijklmnoqrstuvw|Root Entry F 9xxE~Data _Y1Table,WordDocument4FSummaryInformation(hDocumentSummaryInformation8pCompObjq  FMicrosoft Office Word Document MSWordDocWord.Document.89q